Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;24(3):295-305.
doi: 10.5021/ad.2012.24.3.295. Epub 2012 Jul 25.

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Jae-Hong Kim  1 , Sung Yul Lee, Hae-Jin Lee, Na-Young Yoon, Won-Soo Lee
Affiliations

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Jae-Hong Kim et al. Ann Dermatol. 2012 Aug.

Abstract

Background: There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17α-estradiol (Ell-Cranell® alpha 0.025%) solution to Korean female patients with FPHL.

Objective: This study was designed to examine the efficacy and safety of Ell-Cranell® alpha 0.025% solution in Korean female patients with FPHL.

Methods: A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell® alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators.

Results: Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell® alpha 0.025% solution was well tolerated over 8-months period.

Conclusion: This study showed that Ell-Cranell® alpha 0.025% solution is a safe and effective agent for Korean women with FPHL.

Keywords: 17α-estradiol; Ell-Cranell®; Female pattern hair loss.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hair counts from baseline to 4, 8 months after treatment were increased in treated patients, statistically significant (p<0.0001). SD: standard deviation, Min: minimum, max: maximum, CI: confidence internal.
Fig. 2
Fig. 2
Hair diameter from baseline to 4, 8 months after treatment were increased in treated patients, statistically significant (p<0.0001). SD: standard deviation, Min: minimum, max: maximum, CI: confidence interval.
Fig. 3
Fig. 3
Effectiveness of hair regrowth in patients with female pattern hair loss after 8 months treatment. Pt: patient.
Fig. 4
Fig. 4
Investigator assessment of clinical response by duration of the treatment. 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by investigator photographic assessment.
See this image and copyright information in PMC

References

    1. Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998;317:865–869. - PMC - PubMed
    1. Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988;18:1073–1077. - PubMed
    1. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001;145:95–99. - PubMed
    1. Shin HS, Lee SH, Kim DH, An JS, Kwon OS, Eun HC, et al. The efficacy and safety of AP-FHG0604T on female pattern hair loss: a randomized double-blind placebo-controlled clinical trial. Korean J Dermatol. 2007;45:119–126.
    1. Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007;5:391–395. - PubMed